QUIBIM to manage imaging data and AI for European project PARENCHIMA across 25 countries

Presentation of QUIBIM Precision platform at PARENCHIMA meeting in Prague, October 2018

QUIBIM has been selected as the main partner to manage all imaging data and analysis algorithms of the PARENCHIMA initiative, a COST action project initiated in April 2017 with the objective of boosting the use of renal MRI biomarkers to improve the management of chronic kidney disease patients. The leading scientific researchers in medical imaging of the kidney from 25 European countries will be using QUIBIM Precision® platform for highly advanced image analysis. One of the challenges of the project is to centralize the medical imaging data and algorithms from all partners to allow for acquisition protocols and algorithms comparison in terms of quality and precision. The outcome of the project will consist of two new standards for image acquisition and analysis in MR of the kidney.

In the past annual meeting of the consortium in Prague, which took place on 4-5 October, an agreement was established between QUIBIM and PARENCHIMA consortium partners for the selection of QUIBIM Precision platform as the best system for images management and integration of new analysis algorithms.

Steven Sourbron, Lecturer in Magnetic Resonance Imaging at the University of Leeds and project coordinator, expressed “I am delighted that QUIBIM has chosen to partner with PARENCHIMA, helping us to improve outcomes for patients by opening up these promising new methods for use in clinical trials and patient management”. Frank Zöllner, adjunct Professor for medical physics at the University of Heidelberg and leader of working group for PARENCHIMA database and software said “QUIBIM has strong expertise in AI algorithms and managing data and we are confident that they are the right collaborator for this project”. Angel Alberich-Bayarri, CEO of QUIBIM said that ”QUIBIM is excited to be part of this project, which will lead to new standards of image acquisition and analysis in Chronic Kidney Disease (CKD), an unaddressed clinical scenario. I am confident that the impact of this study will be global and improve lives of millions of patients, since it is a disease affecting 10% of population worldwide”

 

About PARENCHIMA

Renal MRI biomarkers are today underused in research and in clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centres is therefore a challenge, and this leads to a significant duplication of efforts, a lack of standardisation in the methods, and difficulties in comparing results between centres. This also limits commercial exploitation, and hinders the set-up of multi-centre trials or translation into clinical practice.

The overall aim of PARENCHIMA is to eliminate the main barriers to the broader study, commercial exploitation and clinical use of renal MRI biomarkers.

PARENCHIMA will coordinate the research of leading European groups in this area to:

  • improve the reproducibility and standardisation of renal MRI biomarkers;
  • increase their availability by developing an open-access toolbox with software and data;
  • demonstrate biological validity and clinical utility in a prospective multicentre clinical study.

In order to increase the impact of this project we are reaching out to join the efforts. More info at: www.renalmri.org

 

About QUIBIM

QUIBIM is a company from Valencia (Spain) which applies artificial intelligence and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology. QUIBIM technology and services are applied in clinical practice, clinical trials, radiology education and research projects. More info at: www.quibim.com

AUTHOR

Angel Alberich-Bayarri

Telecommunications & Electronics Engineer by the Polytechnics University of Valencia. Master in Biomedical Engineering and PhD achieved in 2010 by the Polytechnics University of Valencia, due to his research in the application of advanced image processing techniques to high spatial resolution Magnetic Resonance images for the study of bon estructure. In the profesional aspect, he is scientific-technical director of the Biomedical Imaging Research Group at La Fe Polytechnics and University Hospital and an entrepreneur and co-founder of QUIBIM (Quantitative Imaging Biomarkers in Medicine) company. He previously served as Director of Biomedical Engineering (2012-2014) and R&D engineer (2007-2012) in Quiron Hospital Group. He is the inventor of two patents in the field of medical imaging. He is also the author of over 25 scientific articles, 60 communications to international congresses and 10 book chapters. He has participated in a number of research projects and clinical trials. He is an active member of several scientific societies, among which the European Society of Medical Imaging Informatics (EUSOMII) being a member of the Board. He is also a member of the eHealth and Informatics sucommittee of the European Society of Radiology. In the educational area, he is collaborator of the Polytechnics University of Valencia in the supervision of final projects, theses and PhD’s and of the Faculty of Medicine at the University of Valencia as lecturer at Advanced Medical Imaging. In 2012 he was awarded by the Polytechnic University of Valencia with the Best PhD in the field of ICT’s and by the European Society of Radiology with the Best Scientific Paper Award for its advances in the application of engineering to the study of cardiovascular remodeling. In 2013 he received the Pro-European Academy Prize award, given to leading scientists exemplary groups in science and academic life. In 2014 he was recognized by the European Society of Radiology with the award for the best scientific contribution in the field of oncology. In November 2015 he was awarded by the Massachussets Institute of Technology (MIT) official publication MIT Technology Review, with the award "MIT Innovators Under 35".

All stories by: Angel Alberich-Bayarri

Comments are closed.